{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:05:22Z","timestamp":1790255122774,"version":"4.1.0"},"reference-count":204,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["CA266354"],"award-info":[{"award-number":["CA266354"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omton.2026.201281","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:46:37Z","timestamp":1782517597000},"page":"201281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mechanisms of resistance to BTK inhibitors in B cell malignancies and emerging targeted strategies"],"prefix":"10.1016","volume":"34","author":[{"given":"Qinyu","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5762-8937","authenticated-orcid":false,"given":"Lixin","family":"Rui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201281_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.omton.2026.201281_bib2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton's tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2026.201281_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25042208","article-title":"Bruton's Tyrosine Kinase Inhibitors: Recent Updates","volume":"25","author":"Fares","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2026.201281_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26237411","article-title":"The Development of BTK Inhibitors: A Five-Year Update","volume":"26","author":"Tasso","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.omton.2026.201281_bib6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","article-title":"Inhibitors targeting Bruton\u2019s tyrosine kinase in cancers: drug development advances","volume":"35","author":"Wen","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201281_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omton.2026.201281_bib8","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/361226a0","article-title":"The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases","volume":"361","author":"Vetrie","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201281_bib9","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","article-title":"Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances","volume":"35","author":"Wen","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201281_bib10","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.2013.53.1046","article-title":"Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies","volume":"32","author":"Ponader","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib11","series-title":"Advances in Immunology","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-800266-7.00004-2","article-title":"Chapter One - B-Cell Receptor Signaling in Lymphoid Malignancies and Autoimmunity","author":"Avalos","year":"2014"},{"key":"10.1016\/j.omton.2026.201281_bib12","series-title":"Clinical Immunology","first-page":"47","article-title":"4 - Antigen receptor genes, gene products, and co-receptors","author":"Schroeder","year":"2013"},{"key":"10.1016\/j.omton.2026.201281_bib13","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2026.201281_bib14","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41467-019-08677-1","article-title":"Differential organization of tonic and chronic B cell antigen receptors in the plasma membrane","volume":"10","author":"Gomes de Castro","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201281_bib15","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cell.2009.08.041","article-title":"PI3 Kinase Signals BCR-Dependent Mature B Cell Survival","volume":"139","author":"Srinivasan","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201281_bib16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1146\/annurev.pharmtox.44.101802.121440","article-title":"ErbB receptors: directing key signaling networks throughout life","volume":"44","author":"Holbro","year":"2004","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.omton.2026.201281_bib17","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.str.2024.09.024","article-title":"The mechanism of allosteric activation of SYK kinase derived from multiple phospho-ITAM-bound structures","volume":"32","author":"Bradshaw","year":"2024","journal-title":"Structure"},{"key":"10.1016\/j.omton.2026.201281_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.591577","article-title":"Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies","volume":"10","author":"Ondrisova","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib19","doi-asserted-by":"crossref","first-page":"14157","DOI":"10.1073\/pnas.1107747108","article-title":"Inhibition of PI3K binding to activators by serine phosphorylation of PI3K regulatory subunit p85alpha Src homology-2 domains","volume":"108","author":"Lee","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201281_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1074-7613(00)80591-9","article-title":"BLNK: a central linker protein in B cell activation","volume":"9","author":"Fu","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.omton.2026.201281_bib21","doi-asserted-by":"crossref","first-page":"6942","DOI":"10.1038\/s41467-022-34574-1","article-title":"Conformational motions and ligand-binding underlying gating and regulation in IP3R channel","volume":"13","author":"Fan","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201281_bib22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","article-title":"BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies","volume":"15","author":"Alu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib23","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1126\/science.280.5366.1082","article-title":"RasGRP, a Ras guanyl nucleotide- releasing protein with calcium- and diacylglycerol-binding motifs","volume":"280","author":"Ebinu","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201281_bib24","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/j.1460-2075.1995.tb07316.x","article-title":"Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation","volume":"14","author":"Marais","year":"1995","journal-title":"EMBO J."},{"key":"10.1016\/j.omton.2026.201281_bib25","doi-asserted-by":"crossref","first-page":"7948","DOI":"10.1038\/sj.onc.1203362","article-title":"ERK activation induces phosphorylation of Elk-1 at multiple S\/T-P motifs to high stoichiometry","volume":"18","author":"Cruzalegui","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.omton.2026.201281_bib26","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s001090050063","article-title":"Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways","volume":"74","author":"Whitmarsh","year":"1996","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.omton.2026.201281_bib27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.expneurol.2019.04.016","article-title":"Bridging the gap: Mechanisms of plasticity and repair after pediatric TBI","volume":"318","author":"Sta Maria","year":"2019","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.omton.2026.201281_bib28","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a003004","article-title":"Antigen receptor signaling to NF-kappaB via CARMA1, BCL10, and MALT1","volume":"2","author":"Thome","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.omton.2026.201281_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.cr.7290257","article-title":"Activation and signaling of the p38 MAP kinase pathway","volume":"15","author":"Zarubin","year":"2005","journal-title":"Cell Res."},{"key":"10.1016\/j.omton.2026.201281_bib30","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1084\/jem.20020408","article-title":"Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha","volume":"195","author":"Saijo","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omton.2026.201281_bib31","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omton.2026.201281_bib32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1042\/BST0370217","article-title":"A complex interplay between Akt, TSC2 and the two mTOR complexes","volume":"37","author":"Huang","year":"2009","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.omton.2026.201281_bib33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.semcdb.2014.09.011","article-title":"Growing knowledge of the mTOR signaling network","volume":"36","author":"Huang","year":"2014","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.omton.2026.201281_bib34","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1182\/blood-2005-01-0191","article-title":"Src homology 2 domain-containing inositol-5-phosphatase 1 (SHIP1) negatively regulates TLR4-mediated LPS response primarily through a phosphatase activity- and PI-3K-independent mechanism","volume":"105","author":"An","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib35","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ni.2094","article-title":"Malignant pirates of the immune system","volume":"12","author":"Rui","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omton.2026.201281_bib36","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/PPO.0000000000000412","article-title":"Bruton Tyrosine Kinase Inhibitors: Present and Future","volume":"25","author":"Burger","year":"2019","journal-title":"Cancer J."},{"key":"10.1016\/j.omton.2026.201281_bib37","doi-asserted-by":"crossref","first-page":"9587","DOI":"10.1074\/jbc.274.14.9587","article-title":"Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]","volume":"274","author":"Mahajan","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omton.2026.201281_bib38","series-title":"Ibrutinib Improves Survival for Younger People with Diffuse Large B-Cell Lymphoma","year":"2021"},{"key":"10.1016\/j.omton.2026.201281_bib39","series-title":"AbbVie Withdraws Ibrutinib MCL and MZL Indications in the United States","author":"Rosa","year":"2023"},{"key":"10.1016\/j.omton.2026.201281_bib40","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13045-016-0313-y","article-title":"Second-generation inhibitors of Bruton tyrosine kinase","volume":"9","author":"Wu","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib41","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.omton.2026.201281_bib42","article-title":"Cardiovascular Adverse Effects of Novel Bruton Tyrosine Kinase Inhibitors: What All Cardiologists Should Know","author":"Ng","year":"2023","journal-title":"American Collage of Cardiology)"},{"key":"10.1016\/j.omton.2026.201281_bib43","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/bloodadvances.2023012221","article-title":"BTK inhibitors in CLL: second-generation drugs and beyond","volume":"8","author":"Tam","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201281_bib44","author":"Stewart"},{"key":"10.1016\/j.omton.2026.201281_bib45","author":"Stewart"},{"key":"10.1016\/j.omton.2026.201281_bib46","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40265-020-01318-8","article-title":"Tirabrutinib: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.omton.2026.201281_bib47","unstructured":"Ryan C. Orelabrutinib Wins Approval in China for First-Line CLL and SLL. OncLive 2025. https:\/\/www.onclive.com\/view\/orelabrutinib-wins-approval-in-china-for-first-line-cll-and-sll."},{"key":"10.1016\/j.omton.2026.201281_bib48","unstructured":"Lu C. InnoCare Announces Breakthrough Therapy Designation of Orelabrutinib by US FDA for Treatment of R\/R MCL. InnoCare Pharma 2021. https:\/\/www.prnewswire.com\/news-releases\/innocare-announces-breakthrough-therapy-designation-of-orelabrutinib-by-us-fda-for-treatment-of-rr-mcl-301320811.html."},{"key":"10.1016\/j.omton.2026.201281_bib49","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201281_bib50","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201281_bib51","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.omton.2026.201281_bib52","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in Previously Treated Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201281_bib53","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201281_bib54","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3324\/haematol.2018.192328","article-title":"Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2","volume":"103","author":"Barr","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201281_bib55","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis","volume":"4","author":"Noy","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201281_bib56","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.bbmt.2019.06.023","article-title":"Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b\/2 Study","volume":"25","author":"Waller","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201281_bib57","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","article-title":"Ibrutinib for patients with rituximab-refractory Waldenstr\u00f6m's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib58","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib59","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201281_bib60","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2026.201281_bib61","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib62","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO-25-00690","article-title":"Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib63","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib64","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.22.02830","article-title":"Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstr\u00f6m Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib65","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1182\/bloodadvances.2023010668","article-title":"Safety and efficacy of zanubrutinib in relapsed\/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study","volume":"7","author":"Opat","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201281_bib66","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1200\/JCO-25-00758","article-title":"Zanubrutinib and Venetoclax for Patients With Treatment-Na\u00efve Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma With and Without Del(17p)\/TP53 Mutation: SEQUOIA Arm D Results","volume":"43","author":"Shadman","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib67","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1200\/JCO.22.00510","article-title":"Zanubrutinib Versus Ibrutinib in Relapsed\/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial","volume":"41","author":"Hillmen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib68","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib69","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201281_bib70","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1200\/JCO.23.00562","article-title":"Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib71","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1200\/JCO.2025.43.16_suppl.2019","article-title":"Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the phase II PROSPECT study","volume":"43","author":"Nayak","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib72","unstructured":"Karlovitch S. Orelabrutinib Lands FDA Breakthrough Therapy Designation for R\/R MCL. Targeted Oncol 2021. https:\/\/www.targetedonc.com\/view\/orelabrutinib-lands-fda-breakthrough-therapy-designation-for-r-r-mcl."},{"key":"10.1016\/j.omton.2026.201281_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0290872","article-title":"Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib","volume":"18","author":"Lin","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2026.201281_bib74","first-page":"62","article-title":"Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor","volume":"142","author":"Gomez","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib75","first-page":"3137","article-title":"Pirtobrutinib: a new hope for patients with BTK inhibitor\u2013refractory lymphoproliferative disorders","volume":"141","author":"Thompson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib76","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1158\/1078-0432.CCR-23-1272","article-title":"FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma","volume":"30","author":"Telaraja","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201281_bib77","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nchembio.481","article-title":"Specific Btk inhibition suppresses B cell\u2013 and myeloid cell\u2013mediated arthritis","volume":"7","author":"Di Paolo","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.omton.2026.201281_bib78","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjh.18418","article-title":"Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","volume":"200","author":"Nakhoda","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2026.201281_bib79","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051328","article-title":"Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas","volume":"12","author":"George","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201281_bib81","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abg5216","article-title":"Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK","volume":"15","author":"Dhami","year":"2022","journal-title":"Sci. Signal."},{"key":"10.1016\/j.omton.2026.201281_bib82","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/leu.2016.153","article-title":"Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant","volume":"31","author":"Hamasy","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201281_bib83","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3390\/genes16091064","article-title":"Resistance Mutations in CLL: Genetic Mechanisms Shaping the Future of Targeted Therapy","volume":"16","author":"Sekeres","year":"2025","journal-title":"Genes"},{"key":"10.1016\/j.omton.2026.201281_bib84","doi-asserted-by":"crossref","first-page":"68833","DOI":"10.18632\/oncotarget.11932","article-title":"Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL","volume":"7","author":"Sharma","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2026.201281_bib85","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/ijc.32502","article-title":"Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib","volume":"146","author":"G\u00e1ng\u00f3","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omton.2026.201281_bib86","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood.2024026672","article-title":"Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors","volume":"145","author":"Tam","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib87","doi-asserted-by":"crossref","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201281_bib88","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41375-021-01123-6","article-title":"BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib","volume":"35","author":"Estupin\u00e1n","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201281_bib89","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201281_bib90","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211072839","article-title":"MYD88(L265P) and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy","volume":"13","author":"Chen","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.omton.2026.201281_bib91","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3390\/cancers7020812","article-title":"Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic Implications","volume":"7","author":"Lenz","year":"2015","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201281_bib92","doi-asserted-by":"crossref","first-page":"e1051","DOI":"10.1016\/j.clml.2022.08.006","article-title":"The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review","volume":"22","author":"Xu","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.omton.2026.201281_bib93","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1084\/jem.20131424","article-title":"Consequences of the recurrent MYD88L265P somatic mutation for B cell tolerance","volume":"211","author":"Wang","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omton.2026.201281_bib94","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P Somatic Mutation in Waldenstr\u00f6m's Macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201281_bib95","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clml.2014.01.007","article-title":"Status of PI3K\/Akt\/mTOR pathway inhibitors in lymphoma","volume":"14","author":"Westin","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.omton.2026.201281_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13163949","article-title":"The Pathogenic Role of PI3K\/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review","volume":"13","author":"Rascio","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201281_bib97","doi-asserted-by":"crossref","first-page":"14304","DOI":"10.3390\/molecules190914304","article-title":"Inhibition of the PI3K\/Akt\/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance","volume":"19","author":"Majchrzak","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.omton.2026.201281_bib98","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib99","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc1819","article-title":"Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis","volume":"6","author":"Cully","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2026.201281_bib100","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1200\/JCO.2009.24.0317","article-title":"MicroRNAs in Cancer: Small Molecules With a Huge Impact","volume":"27","author":"Iorio","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib101","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1038\/emboj.2013.178","article-title":"MicroRNA-17\u223c92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways","volume":"32","author":"Jin","year":"2013","journal-title":"EMBO J."},{"key":"10.1016\/j.omton.2026.201281_bib102","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41556-018-0205-1","article-title":"mTOR as a central hub of nutrient signalling and cell growth","volume":"21","author":"Kim","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.omton.2026.201281_bib103","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K Pathway in Human Disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201281_bib104","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201281_bib105","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-15-1965","article-title":"Disruption of in vivo Chronic Lymphocytic Leukemia Tumor\u2013Microenvironment Interactions by Ibrutinib \u2013 Findings from an Investigator-Initiated Phase II Study","volume":"22","author":"Niemann","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201281_bib106","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13045-023-01496-4","article-title":"Beyond Bruton\u2019s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody\u2013drug conjugates, CAR T-cells, and novel agents","volume":"16","author":"Jain","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910442","article-title":"B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy","volume":"22","author":"Alam","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2026.201281_bib108","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/blood-2014-04-571786","article-title":"BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma","volume":"125","author":"Correia","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib109","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.V82.6.1820.1820","article-title":"bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia","volume":"82","author":"Hanada","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12032-021-01470-5","article-title":"Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma","volume":"38","author":"Li","year":"2021","journal-title":"Med. Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib111","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ccr.2010.10.030","article-title":"BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma","volume":"18","author":"Mandelbaum","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201281_bib112","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1158\/2159-8290.CD-15-0507","article-title":"MYC, Metabolism, and Cancer","volume":"5","author":"Stine","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201281_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2025.101273","article-title":"BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies","volume":"71","author":"Liu","year":"2025","journal-title":"Blood Rev."},{"key":"10.1016\/j.omton.2026.201281_bib114","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-021-01111-4","article-title":"MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies","volume":"14","author":"Ahmadi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib115","article-title":"Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma","volume":"5","author":"Hoang","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.omton.2026.201281_bib116","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22062841","article-title":"Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer","volume":"22","author":"Fairlie","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2026.201281_bib117","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1182\/bloodadvances.2018016048","article-title":"Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma","volume":"2","author":"Lee","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201281_bib118","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau1167","article-title":"Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201281_bib119","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1182\/blood.2023020142","article-title":"EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma","volume":"142","author":"Liu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib120","article-title":"The Role of the Transcription Factor EGR1 in Cancer","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib121","doi-asserted-by":"crossref","first-page":"E7260","DOI":"10.1073\/pnas.1610970113","article-title":"Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma","volume":"113","author":"Rui","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201281_bib122","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/1541-7786.MCR-21-0267","article-title":"EGR1 Addiction in Diffuse Large B-cell Lymphoma","volume":"19","author":"Kimpara","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.omton.2026.201281_bib123","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.4049\/jimmunol.181.7.4590","article-title":"Early growth response genes regulate B cell development, proliferation, and immune response","volume":"181","author":"Gururajan","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201281_bib124","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2025.1596636","article-title":"Emerging roles of pyruvate dehydrogenase phosphatase 1: a key player in metabolic health","volume":"16","author":"Kumar","year":"2025","journal-title":"Front. Physiol."},{"key":"10.1016\/j.omton.2026.201281_bib125","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4161\/epi.28324","article-title":"The de novo DNA methyltransferase DNMT3A in development and cancer","volume":"9","author":"Chen","year":"2014","journal-title":"Epigenetics"},{"key":"10.1016\/j.omton.2026.201281_bib126","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1158\/2159-8290.CD-16-0850","article-title":"Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells","volume":"7","author":"Ruella","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201281_bib127","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.3390\/ijms22136995","article-title":"Macrophage Polarization States in the Tumor Microenvironment","volume":"22","author":"Boutilier","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2026.201281_bib128","doi-asserted-by":"crossref","first-page":"8412","DOI":"10.3390\/ijms21218412","article-title":"CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4","volume":"21","author":"Korbecki","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2026.201281_bib129","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jare.2024.08.023","article-title":"Dialog between mantle cell lymphoma cells and lymphoma-associated macrophages underlies ibrutinib resistance","volume":"73","author":"Sun","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.omton.2026.201281_bib130","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.4049\/jimmunol.1202246","article-title":"IL-4 in the brain: a cytokine to remember","volume":"189","author":"Gadani","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201281_bib131","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.18632\/oncotarget.14588","article-title":"Dual SYK\/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment","volume":"8","author":"Guo","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2026.201281_bib132","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.2147\/OTT.S249586","article-title":"Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects","volume":"13","author":"Zhou","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.omton.2026.201281_bib133","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell\u2013derived factor-1","volume":"96","author":"Burger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib134","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/leu.2014.122","article-title":"Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study","volume":"28","author":"Herman","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201281_bib135","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-15-1965","article-title":"Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study","volume":"22","author":"Niemann","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201281_bib136","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.3324\/haematol.2015.137265","article-title":"Ibrutinib and idelalisib target B cell receptor- but not CXCL12\/CXCR4-controlled integrin-mediated adhesion in Waldenstr\u00f6m macroglobulinemia","volume":"101","author":"de Rooij","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201281_bib137","doi-asserted-by":"crossref","DOI":"10.3390\/cells11142235","article-title":"Integrin Signaling Shaping BTK-Inhibitor Resistance","volume":"11","author":"Polcik","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.omton.2026.201281_bib138","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1158\/1078-0432.CCR-15-0781","article-title":"Treatment with Ibrutinib Inhibits BTK- and VLA-4\u2013Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo","volume":"21","author":"Herman","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201281_bib139","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2004-03-0889","article-title":"Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1\u03b1","volume":"106","author":"Nishio","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib140","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1038\/bcj.2015.74","article-title":"Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients","volume":"5","author":"Boissard","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omton.2026.201281_bib141","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/s41375-024-02301-y","article-title":"Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia","volume":"38","author":"Pozzo","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201281_bib142","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.scr.2010.07.003","article-title":"Prospective isolation of clonogenic mantle cell lymphoma-initiating cells","volume":"5","author":"Chen","year":"2010","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.omton.2026.201281_bib143","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13045-015-0161-1","article-title":"Targeting Wnt pathway in mantle cell lymphoma-initiating cells","volume":"8","author":"Mathur","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib144","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/17474086.2018.1435268","article-title":"Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?","volume":"11","author":"Lampson","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.omton.2026.201281_bib145","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood-2024-199212","article-title":"Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenstr\u00f6m Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study","volume":"144","author":"Seymour","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib146","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3324\/haematol.2022.281538","article-title":"Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma","volume":"108","author":"Li","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201281_bib147","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.23.02470","article-title":"Glofitamab in Relapsed\/Refractory Mantle Cell Lymphoma: Results From a Phase I\/II Study","volume":"43","author":"Phillips","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib148","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.2023021306","article-title":"CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study","volume":"143","author":"Minson","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib149","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2024-194839","article-title":"Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed\/Refractory (R\/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a\/b Study","volume":"144","author":"Shah","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib150","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ccell.2016.12.003","article-title":"Simultaneous Inhibition of PI3K\u03b4 and PI3K\u03b1 Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-\u03baB and AKT","volume":"31","author":"Paul","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201281_bib151","doi-asserted-by":"crossref","first-page":"42232","DOI":"10.18632\/oncotarget.6273","article-title":"Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma","volume":"6","author":"Nagel","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2026.201281_bib152","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/blood.2022016934","article-title":"NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts","volume":"141","author":"Zhang","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib153","author":"Plieth"},{"key":"10.1016\/j.omton.2026.201281_bib154","author":"Allan"},{"key":"10.1016\/j.omton.2026.201281_bib155","doi-asserted-by":"crossref","first-page":"4422.1","DOI":"10.1182\/blood-2024-194009","article-title":"A Phase 1 Study of AC676, a Novel BTK Chimeric Degrader, in Patients with B-Cell Malignancies","volume":"144","author":"Tees","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib156","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1182\/bloodadvances.2021006555","article-title":"A phase 1 trial of copanlisib plus ibrutinib in relapsed\/refractory mantle cell lymphoma","volume":"6","author":"Qualls","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201281_bib157","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(24)00682-X","article-title":"Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"26","author":"Wang","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib158","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood.2024024510","article-title":"Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed\/refractory CLL: the phase 1b BRUIN trial","volume":"144","author":"Roeker","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib159","doi-asserted-by":"crossref","DOI":"10.1172\/JCI165694","article-title":"Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma","volume":"133","author":"Jiang","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omton.2026.201281_bib160","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2017-10-809210","article-title":"Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma","volume":"131","author":"Battistello","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib161","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41419-022-04684-1","article-title":"Dual BTK\/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma","volume":"13","author":"Thieme","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omton.2026.201281_bib162","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood-2015-04-639542","article-title":"Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib163","doi-asserted-by":"crossref","first-page":"7008","DOI":"10.1200\/JCO.2024.42.16_suppl.7008","article-title":"Glofitamab monotherapy in patients with heavily pretreated relapsed\/refractory (R\/R) mantle cell lymphoma (MCL): Updated analysis from a phase I\/II study","volume":"42","author":"Phillips","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib164","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2024-199708","article-title":"Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R\/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1","volume":"144","author":"Danilov","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib165","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s43018-025-00921-6","article-title":"Odronextamab monotherapy in patients with relapsed\/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial","volume":"6","author":"Kim","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.omton.2026.201281_bib166","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib167","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","article-title":"Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia","volume":"6","author":"Gill","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201281_bib168","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jtct.2023.12.049","article-title":"Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed\/Refractory B-Cell Lymphoma: A Phase I\/II Study of Safety, Efficacy and Immune Correlative Analysis","volume":"30","author":"Poh","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.omton.2026.201281_bib169","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib170","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib171","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201281_bib172","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood.2024024667","article-title":"Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: final comparative analysis of ALPINE","volume":"144","author":"Brown","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib173","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1111\/cas.14561","article-title":"A multicenter, open-label, phase II study of tirabrutinib (ONO\/GS-4059) in patients with Waldenstr\u00f6m's macroglobulinemia","volume":"111","author":"Sekiguchi","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.omton.2026.201281_bib174","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1182\/bloodadvances.2022009168","article-title":"Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1\/2, open-label, multicenter, single-arm study","volume":"7","author":"Deng","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201281_bib175","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201281_bib176","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2026.201281_bib177","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2159-8290.CD-23-0670","article-title":"First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia and B-Cell Non\u2013Hodgkin Lymphoma","volume":"14","author":"Woyach","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201281_bib178","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201281_bib179","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.3390\/ijms25105246","article-title":"A Review of Resistance Mechanisms to Bruton\u2019s Kinase Inhibitors in Chronic Lymphocytic Leukemia","volume":"25","author":"Wi\u015bniewski","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2026.201281_bib180","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2019-127674","article-title":"Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib181","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of Resistance to Noncovalent Bruton\u2019s Tyrosine Kinase Inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201281_bib182","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2015-02-626846","article-title":"Hypermorphic mutation of phospholipase C, \u03b32 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation","volume":"126","author":"Liu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib183","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1182\/blood-2024-200896","article-title":"Prevalence of BTK and PLCG2 Mutations in BTK Inhibitor Treated CLL Patients Who Experience Disease Progression: A Meta-Analysis","volume":"144","author":"Molica","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib184","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-020-00924-z","article-title":"Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies","volume":"13","author":"He","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib185","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/bloodadvances.2022008121","article-title":"Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models","volume":"7","author":"Lim","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201281_bib186","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omton.2026.201281_bib187","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","article-title":"Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation","volume":"57","author":"Buhimschi","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.omton.2026.201281_bib188","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1182\/blood-2024-204184","article-title":"Nx-2127 and Nx-5948, Two Clinical Stage Cereblon-Recruiting BTK Degraders, Facilitate T Cell Functionality in Chronic Lymphocytic Leukemia","volume":"144","author":"Huynh","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib189","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2023-179872","article-title":"A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed\/Refractory B Cell Malignancies","volume":"142","author":"Danilov","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib190","unstructured":"Cortese T. In: Conroy R., editor. NX-5948 Earns Fast Track Designation in R\/R Waldenstr\u00f6m Macroglobulinemia. Cancer Network 2024. https:\/\/www.cancernetwork.com\/view\/nx-5948-earns-fast-track-designation-in-r-r-waldenstr-m-macroglobulinemia."},{"key":"10.1016\/j.omton.2026.201281_bib191","doi-asserted-by":"crossref","first-page":"38591","DOI":"10.18632\/oncotarget.5774","article-title":"MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management","volume":"6","author":"Cai","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2026.201281_bib192","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14920","article-title":"Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma","volume":"8","author":"Zhao","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201281_bib193","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41420-022-01289-7","article-title":"CD52 and OXPHOS\u2014potential targets in ibrutinib-treated mantle cell lymphoma","volume":"8","author":"Fuhr","year":"2022","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.omton.2026.201281_bib194","doi-asserted-by":"crossref","first-page":"24980","DOI":"10.18632\/oncotarget.25166","article-title":"Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells","volume":"9","author":"Vangapandu","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2026.201281_bib195","doi-asserted-by":"crossref","DOI":"10.3390\/jpm15020051","article-title":"The Development and Application of Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma","volume":"15","author":"Sun","year":"2025","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.omton.2026.201281_bib196","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-014-0058-4","article-title":"New antibody approaches to lymphoma therapy","volume":"7","author":"Suresh","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201281_bib197","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.3324\/haematol.2012.082248","article-title":"Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells","volume":"98","author":"Wong","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201281_bib198","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/bloodadvances.2019000025","article-title":"Long-term outcome of patients with relapsed\/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab","volume":"3","author":"Dufner","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201281_bib199","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1182\/blood-2019-126186","article-title":"A CD19\/CD3 Bispecific Antibody Induces Superior T Cell Responses Against Chronic Lymphocytic Leukemia When Combined with Ibrutinib","volume":"134","author":"Mhibik","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib200","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/blood.2023020554","article-title":"Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial","volume":"143","author":"Papazoglou","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib201","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1111\/bjh.16406","article-title":"The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity","volume":"189","author":"Godwin","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2026.201281_bib202","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2021.100826","article-title":"CAR T-cell therapy for B-cell lymphoma","volume":"46","author":"Denlinger","year":"2022","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.omton.2026.201281_bib203","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201281_bib204","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/ijc.33212","article-title":"Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients","volume":"148","author":"Fan","year":"2021","journal-title":"Int. J. Cancer"}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:36:39Z","timestamp":1790253399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926001578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":204,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2950329926001578"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201281","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of resistance to BTK inhibitors in B cell malignancies and emerging targeted strategies","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201281","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201281"}}